# Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke

> **NCT00604630** · PHASE2,PHASE3 · COMPLETED · sponsor: **Max-Planck-Institute of Experimental Medicine** · enrollment: 522 (actual)

## Conditions studied

- Infarction, Middle Cerebral Artery
- Middle Cerebral Artery Stroke
- Stroke, Acute

## Interventions

- **DRUG:** recombinant human erythropoietin alfa
- **DRUG:** 0.9% NaCl

## Key facts

- **NCT ID:** NCT00604630
- **Lead sponsor:** Max-Planck-Institute of Experimental Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 522 (ACTUAL)
- **Last updated:** 2008-10-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00604630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00604630, "Multicenter Efficacy Study of Recombinant Human Erythropoietin in Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00604630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*